Table 3 Clinical remission at week 17 ± 0.5: univariable analysis of baseline parameters in patients with UC
UC patients with clinical remission | UC patients with no clinical remission | p-value | ||
|---|---|---|---|---|
Disease duration from initial diagnosis (years) | 10.0 ± 1.4 | 7.4 ± 1.1 | 0.09 | M |
Age at initial diagnosis (years) | 35.7 ± 2.4 | 32.7 ± 1.8 | 0.31 | M |
CRP (mg/L) | 10.5 ± 2.4 | 7.6 ± 1.4 | 0.36 | M |
Hb (g/dL) | 13.3 ± 0.4 | 12.4 ± 0.3 | 0.04 | M |
Leukocytes × 103/µL | 9.3 ± 0.5 | 9.4 ± 0.5 | 0.82 | M |
Endoscopic disease activity | 2.3 ± 0.2 | 2.3 ± 0.1 | 0.99 | M |
Clinical disease activity (PMS) | 3.5 ± 0.3 | 4.4 ± 0.2 | 0.02 | M |
Disease extent (E1/E2/E3)/n (%) | (2/22/14)/38 (5/58/37) | (5/28/31)/64 (8/44/48) | 0.38 | C |
First flare treated with corticosteroids (%) | 34/37 (92) | 50/63 (79) | 0.16 | F |
Previous treatment with anti TNF-α antibody (%) | 27/38 (71) | 50/65 (77) | 0.64 | F |
Active smoking (%) | 2/37 (5) | 6/66 (9) | 0.71 | F |
Concomitant corticosteroid therapy (%) | 20/37 (54) | 32/61 (53) | > 0.99 | F |
Prior bowel surgery (%) | 0/38 (0) | 1/66 (2) | > 0.99 | F |
Extraintestinal manifestations (%) | 5/38 (13) | 9/68 (13) | > 0.99 | F |